TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07869147: Study of ORJ-001 for the Treatment of IPF

Sponsor: Oorja Bio, Inc. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 95 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT07869147 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07869147 Rescue Dossier →